JPH07215860A - 皮膚および膣の萎縮を抑制する方法 - Google Patents

皮膚および膣の萎縮を抑制する方法

Info

Publication number
JPH07215860A
JPH07215860A JP6314552A JP31455294A JPH07215860A JP H07215860 A JPH07215860 A JP H07215860A JP 6314552 A JP6314552 A JP 6314552A JP 31455294 A JP31455294 A JP 31455294A JP H07215860 A JPH07215860 A JP H07215860A
Authority
JP
Japan
Prior art keywords
skin
atrophy
compound
active ingredient
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6314552A
Other languages
English (en)
Japanese (ja)
Inventor
George Joseph Cullinan
ジョージ・ジョゼフ・カリナン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JPH07215860A publication Critical patent/JPH07215860A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP6314552A 1993-12-21 1994-12-19 皮膚および膣の萎縮を抑制する方法 Pending JPH07215860A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US171087 1993-12-21
US08/171,087 US5461064A (en) 1993-12-21 1993-12-21 Methods of inhibiting atrophy of the skin and vagina

Publications (1)

Publication Number Publication Date
JPH07215860A true JPH07215860A (ja) 1995-08-15

Family

ID=22622468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6314552A Pending JPH07215860A (ja) 1993-12-21 1994-12-19 皮膚および膣の萎縮を抑制する方法

Country Status (17)

Country Link
US (2) US5461064A (cs)
EP (1) EP0664124B1 (cs)
JP (1) JPH07215860A (cs)
KR (1) KR950016732A (cs)
CN (1) CN1108097A (cs)
AU (1) AU699948B2 (cs)
CA (1) CA2138511A1 (cs)
CZ (1) CZ321594A3 (cs)
DE (1) DE69426690T2 (cs)
ES (1) ES2153851T3 (cs)
HU (1) HUT71221A (cs)
IL (1) IL112041A0 (cs)
NO (1) NO944919L (cs)
NZ (1) NZ270173A (cs)
PH (1) PH31600A (cs)
RU (1) RU2143897C1 (cs)
ZA (1) ZA9410078B (cs)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5847007A (en) 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
JPH11513390A (ja) * 1995-10-06 1999-11-16 アーチ デベロップメント コーポレイション 細胞殺傷のウイルス増強のための方法および組成物
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5827876A (en) * 1996-04-09 1998-10-27 American Home Products Corporation Inhibition of bone loss by 3-(4-acrylamidobenzoyl) benzo b!-thiophenes
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6488940B2 (en) * 1997-08-21 2002-12-03 Johnson & Johnson Consumer Companies, Inc. Use of 17-α-estradiol for the treatment of aged or sundamaged skin and/or skin atrophy
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
CN1250563C (zh) 1999-05-04 2006-04-12 斯特拉坎有限公司 雄激素糖苷及其产生雄性征的活性
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
KR100441167B1 (ko) * 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
AU2003239869A1 (en) * 2002-05-23 2003-12-12 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
MXPA04012220A (es) * 2002-06-06 2005-04-08 Hormos Medical Corp Metodo para la inhibicion de la atrofia o para el tratamiento o la prevencion de los sintomas relacionados con la atrofia en mujeres.
BRPI0711525A2 (pt) 2006-06-02 2011-11-01 Pear Tree Women S Health Care composição farmacêutica e método para tratar sintomas de vaginite atrófica
US8097660B2 (en) * 2006-08-31 2012-01-17 Bayer Materialscience Llc Rigid polyurethane foams with low thermal conductivity and a process for their production
US20080139513A1 (en) * 2006-09-26 2008-06-12 Novavax, Inc. Transdermal deliver of active agents
WO2008099060A2 (en) 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
PL2121553T3 (pl) 2007-02-14 2012-11-30 Hormos Medical Ltd Sposób wytwarzania cennych terapeutycznie pochodnych trifenylobutenu
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
AU2016270753B2 (en) * 2015-06-01 2021-06-17 Durga Enterprises, LLC Compositions for treatment of atrophic vaginitis, peri-and post-menopausal dyspareunia, and/or oophorectomized females and treatment methods therewith
PL3498276T3 (pl) * 2017-12-14 2021-03-08 Ntc S.R.L Zastosowanie ektoiny i pochodnych ektoiny w schorzeniach sromowo-pochwowych

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
SE500453C2 (sv) * 1991-10-07 1994-06-27 Karobio Ab Ett in vitro förfarande för utvärdering av en substans effekter
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
AU672182B2 (en) * 1991-11-27 1996-09-26 Novo Nordisk A/S Piperidine derivatives and their use in treating psychosis

Also Published As

Publication number Publication date
KR950016732A (ko) 1995-07-20
US5461064A (en) 1995-10-24
EP0664124B1 (en) 2001-02-14
IL112041A0 (en) 1995-03-15
RU2143897C1 (ru) 2000-01-10
NO944919L (no) 1995-06-22
CA2138511A1 (en) 1995-06-22
RU94044436A (ru) 1996-10-20
NZ270173A (en) 1996-08-27
PH31600A (en) 1998-11-03
ES2153851T3 (es) 2001-03-16
CZ321594A3 (en) 1995-09-13
DE69426690D1 (de) 2001-03-22
AU8154294A (en) 1995-06-29
DE69426690T2 (de) 2001-08-09
HU9403655D0 (en) 1995-02-28
CN1108097A (zh) 1995-09-13
EP0664124A1 (en) 1995-07-26
HUT71221A (en) 1995-11-28
AU699948B2 (en) 1998-12-17
NO944919D0 (no) 1994-12-19
US5610167A (en) 1997-03-11
ZA9410078B (en) 1996-06-19

Similar Documents

Publication Publication Date Title
JPH07215860A (ja) 皮膚および膣の萎縮を抑制する方法
CA2101356C (en) Improvements in or relating to benzothiophenes
EP0659416B1 (en) Inhibition of seborrhea and acne
JPH07196499A (ja) 更年期症候群の治療法
JPH06234632A (ja) ベンゾチオフェン類を含有する医薬組成物
HUT71478A (en) Pharmaceutical compositions, for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome containing 2-phenyl-3-aroyl-benzothiophene derivatives and process for their preparation
EP0659413B1 (en) Inhibition of CNS problems in post-menopausal women
JPH07215865A (ja) 閉経後女性の性欲を増進するための方法
EP0659414B1 (en) Inhibition of hirsutism and alopecia in women
US5670523A (en) Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
JPH10504577A (ja) 神経損傷を抑制する方法
AU707675B2 (en) Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
TW389693B (en) Pharmaceutical composition for inhibiting skin and vagina atrophy
JPH10504579A (ja) 原発性子宮内膜過形成の抑制法
CA2244247A1 (en) Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20031104